Table 6.
Summary of HPV prevalence by source of heterogeneity (Prevalence; 95% confidence interval)
| Type of cancer | Geographic location | Type of samples analysed | Type of primer used | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Eastern Europe | Western Europe | Unclear | Fixed-biopsy | Others | Not reported | GP5+/GP6+ | MY09/MY11 (not GP5+/GP6+) | Others | Not reported | |
| Base of tongue | 50.0%; 95% CI, 23.7% to 76.3% | 44.5%; 95% CI, 29.4% to 59.5% | 53.7%; 95% CI, 40.9% to 66.6% | 41.5%; 95% CI, 26.9% to 56.1% | Not applicable | 53.7%; 95% CI, 44.6% to 62.8% | 50.0%; 95% CI, 23.7% to 76.3% | Not applicable | 39.5%; 95% CI, 20.2% to 58.8% | 53.7%; 95% CI, 44.6% to 62.8% |
| Hypopharyngeal | Not applicablea | Not applicableb | 60.0%; 95 CI%, 20.3% to 100.0%c | 50.0%; 95 CI%, 21.5% to 78.5% | 48.9%; 95 CI%, 0.0% to 97.9%d | 29.3%; 95 CI%, 12.0% to 46.3% | ||||
| Laryngeal | 27.5%; 95 CI%, 0.0% to 55.1%c | 28.0%; 95 CI%, 14.8% to 41.2% | Not applicable | 32.0%; 95 CI%, 17.0% to 47.1% | 19.7%; 95 CI%, 12.8% to 26.6% | Not applicable | 25.6%; 95 CI%, 5.1% to 46.0% | 56.0%; 95 CI%, 0.0% to 100.0%c,d | 29.6%; 95 CI%, 4.7% to 54.7% | 20.5%; 95 CI%, 14.0% to 26.9% |
| Oral | 34.7%; 95 CI%, 9.4% to 60.0% | 21.3%; 95 CI%, 15.0% to 27.7% | Not applicable | 27.5%; 95% CI, 20.3% to 34.8% | 26.6%; 95% CI, 19.8% to 33.3% | Not applicable | 34.8%; 95 CI%, 17.6% to 52.0% | 34.5%; 95 CI%, 14.2% to 54.8% | 16.9%; 95 CI%, 0.0% to 34.6%c | 16.7%; 95 CI%, 0.0% to 34.6%c |
| Oropharyngeal | 56.9%; 95% CI, 49.5% to 64.3% | 33.7%; 95% CI, 24.2% to 43.2% | Not applicable | 39.6%; 95% CI, 29.7% to 49.5% | 33.3%; 95% CI, 20.4% to 46.2% | 64.0%; 95% CI, 55.4% to 72.7% | 46.8%; 95 CI%, 33.2% to 60.3% | 36.5%; 95 CI%, 0.0% to 73.1%c | 37.8%; 95 CI%, 15.5% to 60.2% | 37.7%; 95 CI%, 19.9% to 55.5% |
| Pharyngeal | 20.0%; 95% CI, 0.0% to 49.4%c | 14.3%; 95% CI, 0.7% to 27.9% | Not applicable | Not applicableb | 29.4%; 95 CI%, 0.0% to 58.8%c | 29.4%; 95 CI%, 0.0% to 58.8%c | 22.1%; 95 CI%, 0.0% to 44.1%c | Not applicable | ||
| Tongue | 12.2%; 95% CI, 0.0% to 24.4% | 32.1%; 95% CI, 0.9% to 63.2% | Not applicable | 34.2%; 95% CI, 0.0% to 68.3% | 21.4%; 95% CI, 10.9% to 32.0% | Not applicable | 12.2%; 95 CI%, 0.0% to 24.4%c | Not applicable | 33.3%; 95 CI%, 0.0% to 100.0%c,d | 21.4%; 95 CI%, 10.9% to 32.0% |
| Tonsillar | 80.4%; 95% CI, 69.7% to 91.1% | 64.2%; 95% CI, 54.1% to 74.3% | Not applicable | 65.0%; 95% CI, 54.2% to 75.8% | Not applicable | 73.3%; 95% CI, 65.6% to 81.1% | 62.4%; 95 CI%, 43.5% to 81.3% | 80.3%; 95 CI%, 68.2% to 92.4% | 62.6%; 95 CI%, 30.0% to 95.1% | 68.7%; 95 CI%, 61.6% to 75.8% |
aAll studies investigated patients from Western Europe.
bThe sources of all cancer types were fixed biopsies.
cAdjusted values to reflect prevalence estimates less than 0.0%.
dAdjusted values to reflect prevalence estimates exceeding 100%.